Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis

Table 4 Day 42 treatment success rate of artemisinin combination therapies among P. falciparum patients

Author	Country	Design	Age	Drugs	Day 42 ACPR (n/N, %)
Davlantes 2018 [25]	Angola	Non-RCT	< 12 years	DP	169/169, 100%
Plucinski 2017 [35]	Angola	Non-RCT	6 m to 12 years	DP	144/145, 99.3%
Premji 2009 [36]	Burkina Faso, Ghana, Kenya, Nigeria, Tanzania	RCT, phase III trial	1 to 15 years	CDA	697/771, 90.4%
Premji 2009 [36]	Burkina Faso, Ghana, Kenya, Nigeria, Tanzania	RCT, phase III trial	1 to 15 years	AL	358/384, 93.2%
Ramharter 2008 [37]	Gabon	Non-RCT	2–14 years	AP 9:3-mg/kg tabs	8/9, 88.9%
Ramharter 2008 [37]	Gabon	Non-RCT	2–14 years	AP 9:3-mg/kg granule	13/14, 92.9%
Sawa 2013 [38]	Kenya	RCT	6 months to 10 years	AL	115/119, 96.6%
Sawa 2013 [38]	Kenya	RCT	6 months to 10 years	DP	129/129, 100%
Total					1633/1740, 93.9%

ISSN: 1471-2334